	Predictors of Pentafecta Failure Despite Trifecta Achievement in Robot-Assisted Partial Nephrectomy. Asian J Endosc Surg Kamisawa K, Takeda T, Nishimoto Y, Tanigawa M, Fukumoto K, Yasumizu Y, Tanaka N, Matsumoto K, Morita S, Kosaka T, Asanuma H, Oya M. PMID: 41120203 [PubMed - indexed for MEDLINE]
	Capivasertib plus abiraterone in PTEN-deficient metastatic hormone-sensitive prostate cancer: CAPItello-281 Phase III study. Ann Oncol Fizazi K, Clarke NW, De Santis M, Uemura H, Fay AP, Karadurmus N, Kwiatkowski M, Alvarez-Fernandez C, Jiang S, Sotelo M, Parslow D, Oliveira N, Kwon TG, Ye D, Boudewijns S, Danchaivijitr P, Rooney C, Gresty C, Yeste-Velasco M, Logan J, George DJ, CAPItello-281 Study Group. PMID: 41120017 [PubMed - as supplied by publisher]
	Lutetium-177 [(177)Lu]Lu-PSMA-I&T plus radium-223 in patients with metastatic castration-resistant prostate cancer (AlphaBet): an interim analysis of the investigator-initiated, single-centre, single-arm, phase 1/2 trial. Lancet Oncol Kostos L, Buteau JP, Xie J, Cardin A, Akhurst T, Alipour R, Au L, Chan J, Chin KY, Emmerson B, Furic L, Garcia Q, Hamilton AJ, Haskali MB, Jackson PA, Kashyap RK, Kong G, MacFarlane L, Murphy DG, Parker BS, Ravi Kumar AS, Saghebi J, Wang Y, Tran B, Azad AA, Hofman MS. PMID: 41119954 [PubMed - as supplied by publisher]
	The predictive value of dual-energy computed tomography radiomics in microvessel of clear cell renal cell carcinoma. Future Oncol Li R, Su X, Li Z, Wang N, Sun H, Ouyang A. PMID: 41120253 [PubMed - as supplied by publisher]
	Management of Renal Cell Carcinoma of Variant Histology. JCO Oncol Pract Prado LC, Jang A, Tariki MS, Tannir NM, Barata PC. PMID: 41118614 [PubMed - as supplied by publisher]
	Single-Arm Pivotal Studies in Bacillus Calmette-GuÃ©rin-Unresponsive Non-Muscle-Invasive Bladder Cancer. J Clin Oncol Bandari J, Messing EM. PMID: 41118609 [PubMed - as supplied by publisher]
	Evaluation of inflammatory markers in survival analysis of patients undergoing radical cystectomy using machine learning. World J Urol Ç, Y, Ta, Kurt Pehlivano, , Ünal M, Teke K. PMID: 41117971 [PubMed - indexed for MEDLINE]
	Risk factors and metastasis prediction in small (â‰¤â€‰4Â cm) clear cell renal cell carcinoma: a nested case-control study. World J Urol Wu Z, Pan D, Ji J, Tian X, Zhang H, Qiu M, Ma L, Zhang S. PMID: 41117842 [PubMed - indexed for MEDLINE]
	Survival Prediction for Postoperative Patients With Kidney Cancer Based on Computed Tomography Radiomics: Retrospective Cohort Study. JMIR Med Inform He G, Lai L, Yu G, Pang H, Yu X, Zhang H, Zhu Q, Lv Y. PMID: 41117752 [PubMed - indexed for MEDLINE]
	Construction and validation of a novel diagnostic model with palmitoylation-related genes for prostate cancer. Cytotechnology Fu L, Huang J, Sun Y, Jia Y. PMID: 41116964 [PubMed]
	[Options in nuclear medicine for advanced prostate cancer in practice]. Radiologie (Heidelb) Siegmund SC, Kazmierczak PM, Holzgreve A, Stief CG, Casuscelli J, Unterrainer M, Unterrainer LM. PMID: 41115946 [PubMed - as supplied by publisher]
	Novel pembrolizumab-based treatments as first-line therapy in advanced clear cell renal cell carcinoma: Substudy 03A of the open-label, umbrella platform, phase I/II KEYMAKER-U03 trial. Ann Oncol Suarez C, Rojas C, Shin SJ, Weber PY, Albiges L, Motzer R, Hammers H, Peer A, Lee JL, Miller WH Jr, Waddell T, Neiman V, Keizman D, Kloster AZ, Weickhardt A, Dziadziuszko R, Suttner L, Sharma M, Burgents JE, Powles T. PMID: 41115468 [PubMed - as supplied by publisher]
	Durvalumab in combination with BCG for BCG-naive, high-risk, non-muscle-invasive bladder cancer (POTOMAC): final analysis of a randomised, open-label, phase 3 trial. Lancet De Santis M, Palou Redorta J, Nishiyama H, Krawczy, Seyitkuliev A, Novikov A, Guerrero-Ramos F, Zukov R, Kato M, Kawahara T, Goeman L, Puente J, Hellmis E, Powles T, Radziszewski P, Gust KM, Vasey P, Bigot P, Fradet Y, Hunting J, Armstrong J, Boulos S, Hois S, Shore ND, POTOMAC Investigators. PMID: 41115436 [PubMed - as supplied by publisher]
	Prognostic value of lymphocyte to monocyte ratio for the patients with bladder cancer: a systematic review and meta-analysis. Front Oncol Ren Q, Li Y, Chen H, Chen Y. PMID: 41114376 [PubMed]
	Calendar time trends in synchronous metastatic urinary bladder cancer before and after the introduction of immune checkpoint inhibitors: a nation-wide population-based cohort study. Front Oncol Söderkvist K, Häggström C, Hagberg O, Aljabery F, Gårdmark T, Holmberg L, Hosseini A, Jerlström T, Kjölhede H, Malmström PU, Sherif A, Liedberg F, Ullén A. PMID: 41114360 [PubMed]
	Prostate cancer diagnostics: evolution over 30 years and the impact of education level - a prospective population-based study. Front Oncol Will L, Thimansson E, Bengtsson J, Bjartell A, Zackrisson S, Baubeta E. PMID: 41114354 [PubMed]
	Algorithms on the rise: a machine learning-driven survey of prostate cancer literature. Front Oncol Gu S, Chen J, Fan C, Huang X, Li L, Zhang H. PMID: 41114342 [PubMed]
	The Multidisciplinary Role of Echocardiography: From the Thrombus in Inferior Vena Cava to the Diagnosis of Renal Cell Carcinoma. J Cardiovasc Echogr Vraynko E, Andova V, Selim G, Georgievska-Ismail L. PMID: 41114057 [PubMed]
	Meet-URO Score Validation in Real-world Patients with Metastatic Renal Cell Carcinoma Receiving First-line Pembrolizumab Plus axitinib: A Subanalysis of the Prospective ProPAXI Study. J Kidney Cancer VHL Airò G, Guida A, Gili A, Signori A, Rebuzzi SE, Maruzzo M, Lai E, Pierantoni F, Bimbatti D, Basso U, Damassi A, Calabrò F, Cerbone L, Caserta C, Sirgiovanni G, Serafin D, Caffo O, Scagliarini S, Bracarda S, Buti S. PMID: 41113349 [PubMed]
	Combination neoadjuvant therapy with toripalimab and axitinib for renal cell carcinoma with inferior vena cava thrombus: Insights from the NEOTAX study. Indian J Urol Kumar L. PMID: 41112721 [PubMed]

Articles 1 - 20 / 171047

Page 1 of 8553



		Time frame

	Mediscope AG E-mail: info@mediscope.ch
	Disclaimer \| Privacy Policy